This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cimminiello, C. Articles by Bonfardeci, G. Search for Related Content PubMed PubMed Citation Articles by Cimminiello, C. Articles by Bonfardeci, G. Social Bookmarking                         What's this?

Platelet-Derived Growth Factor (PDGF) in Patients with Different Degrees of Chronic Arterial Obstructive Disease

Fourth Internal Medicine Department, Vascular and Thrombotic Pathology, S. Carlo Borromeo General Hospital

Guido Arpaia

Fourth Internal Medicine Department, Vascular and Thrombotic Pathology, S. Carlo Borromeo General Hospital

Manuela Aloisio

Fourth Internal Medicine Department, Vascular and Thrombotic Pathology, S. Carlo Borromeo General Hospital

Tiziano Uberti

Fourth Internal Medicine Department, Vascular and Thrombotic Pathology, S. Carlo Borromeo General Hospital

Florica Rossi

Fourth Internal Medicine Department, Vascular and Thrombotic Pathology, S. Carlo Borromeo General Hospital

Francesca Pozzi

Radioimmunology Laboratory, S. Carlo Borromeo General Hospital, Milan, Italy

Giuseppe Bonfardeci

Fourth Internal Medicine Department, Vascular and Thrombotic Pathology, S. Carlo Borromeo General Hospital

Platelet activation and platelet-derived growth factor (PDGF) play a pivotal role in the pathogenesis of atherosclerosis. Evidence has been accumulating that in the evolution of chronic arterial obstructive disease (CAOD) platelets are also crucially important. The aim of the present study was, therefore, to assess plasma levels of PDGF in patients with different degrees of CAOD according to Fontaine.

Twenty patients (17 men, 3 women, mean age sixty-eight ± seven years) with inter mittent claudication (Fontaine stage II) entered the study and their PDGF levels were assessed by radioimmunoassay. Ten additional patients (7 men, 3 women, mean age seventy-three ± seven years) with more severe CAOD (leg pain at rest/skin ulcers) were also studied. Ten healthy subjects (6 men, 4 women, mean age fifty-four ±six years) comprised the control group. Patients in stage II were reinvestigated after sixty days of a "training" procedure.

Patients with both intermittent claudication and more severe disease had higher levels of PDGF than controls (controls 165.9 ±119.1 pg/mL; Fontaine stage II 403.5 ±218.4; Fontaine stage III/IV 578.1 ±637.2: ANOVA P = 0.04) with no difference between the two groups of patients. After the training period, PDGF levels were signifi cantly higher than at baseline (863.7 ±819.6 pg/mL vs 403.5 ±218.4) but without signif icant improvement of physical performance. (continued on next page)

The elevation of PDGF levels in blood from CAOD patients could be the result of marked platelet activation due to interaction with a widely damaged peripheral vascula ture. The same was not true for coronary heart disease, in which normal values of PDGF in venous blood were found. Nevertheless, as in acute coronary syndromes, PDGF increases when the clinical picture improves, perhaps in relation to its reduced consump tion in vessel walls.

Angiology, Vol. 45, No. 4, 289-293 (1994)
DOI: 10.1177/000331979404500405


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]